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Abstract
We have recently observed that the corticotrophin releasing hormone (CRF) related peptide
urocortin (UCN) reverses key features of nigrostriatal damage in the hemiparkinsonian 6-
hydroxydopamine lesioned rat. Here we have studied whether similar effects are also evident in
the lipopolysaccaride (LPS) neuroinflammatory paradigm of Parkinson's disease (PD). To do this we
have measured restoration of normal motor behaviour, retention of nigral dopamine (DA) and also
tyrosine hydroxylase (TH) activity. Fourteen days following intranigral injections of LPS and UCN,
rats showed only modest circling after DA receptor stimulation with apomorphine, in contrast to
those given LPS and vehicle where circling was pronounced. In separate experiments, rats received
UCN seven days following LPS, and here apomorphine challenge caused near identical circling
intensity to those that received LPS and UCN concomitantly. In a similar and consistent manner
with the preservation of motor function, UCN 'protected' the nigra from both DA depletion and
loss of TH activity, indicating preservation of DA cells. The effects of UCN were antagonised by
the non-selective CRF receptor antagonist α-helical CRF and were not replicated by the selective
CRF2 ligand UCN III. This suggests that UCN is acting via CRF1 receptors, which have been shown
to be anti-inflammatory in the periphery. Our data therefore indicate that UCN is capable of
maintaining adequate nigrostriatal function in vivo, via CRF1  receptors following a neuro-
inflammatory challenge. This has potential therapeutic implications in PD.
Findings
Parkinson's disease (PD) is largely the result of a degener-
ation of nigrostriatal neurons. Before the disease presents
clinically, death of dopamine (DA) neurons occurs in the
substantia nigra pars compacta (SNc) asymptomatically.
This has traditionally been ascribed to concurrent apop-
totic, excitotoxic and free-radical mediated events [1,2]
Recent evidence suggests that both pre- and postnatal neu-
roinflammation may play a crucial predisposing or causa-
tive role in the aetiology of PD [3,4]. Prevention of
nigrostriatal neuronal destruction once established, or
prior to lesion development, represents an ideal future
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therapeutic goal in PD. Urocortin (UCN), a cortico-
trophin releasing hormone (CRF) related peptide has
recently been proposed as a cytoprotectant. Evidence for
this exists in a range of tissues including neuronal cells
[5,6]. Interestingly UCN, acting via CRF1 receptors, is anti-
inflammatory in the periphery [7]. We have recently
observed that UCN arrests the development of Parkinso-
nian like features in the 6-hyroxydopamine lesioned
hemiparkinsonian rat [8]. UCN substantially reverses
apomorphine-induced circling, loss of tissue DA, loss of
nigral and striatal tyrosine hydroxylase (TH) activity and
loss of TH protein levels [8]. Although the 6-OHDA
model of PD is well established it has significant physio-
logical limitations. In contrast, lipopolysaccaride (LPS) is
an established product of bacterial infection, including
relatively common conditions such as bacterial vaginitis.
Significantly, evidence suggests that systemic inflamma-
tion can predispose or be causative in the genesis of PD
[3,4]. Therefore, exposure to conditions leading to neu-
roinflammation, a condition to which the SNc in particu-
larly susceptible, constitutes a realistic mechanism by
which the disease may be initiated. Here we have investi-
gated the potential protective effects of UCN in the LPS
paradigm of PD. Additionally, we have studied the effects
of the non-selective CRF receptor antagonist α-helical CRF
and also urocortin III (UCN III), a selective CRF2 agonist
[9], on indices of nigral DA neuronal integrity to deter-
mine whether effects of UCN are receptor mediated and
the likely subtype.
UCN, UCN III, LPS, α-helical CRF and apomorphine were
all obtained from Sigma, UK. The latter agent was dis-
solved in 0.2% w/v ascorbic acid, whilst LPS, α-helical
CRF, UCN and UCN III were initially dissolved in water
and further diluted in saline. The concentration of UCN
chosen is identical to that used in previous investigations
[8,10,11]. Apomorphine was injected in a volume of 0.1
ml per 100 g body weight. Experiments were performed in
accordance with the Animals (Scientific Procedures) Act,
UK (1986). Male Wistar rats (Charles River, UK; 210–240
g) were group housed with food and water ad libitum. Ani-
mals were anaesthetised, secured in a stereotaxic frame
and given injections of LPS (2 μg/2 μl) into SNc (from
bregma in mm; A -5.2, L 2.2 and V 8.3). Animals co-
treated with UCN, UCN III or α-helical CRF received
injections (20 fmols/2 μl) directly into the ipsilateral SNc
whereas those not receiving UCN were given vehicle.
UCN itself was administered either concomitantly with
LPS or 7 days later (i.e. once lesions were clearly evident;
Fig. 1). All intracerebral injections were performed using a
stereotaxic frame mounted microsyringe (Hamilton, US)
over approximately four minutes (0.5 μl/min.) and the
needle left in place for five min post-injection. Fourteen
days after toxin administration (seven days in certain
experiments, Fig. 1) rats were given apomorphine (0.5
mg/kg, s.c.) and rotations measured 30 min later for 2
min in a circular 'arena', approximately 1 metre in diame-
ter, to estimate lesion severity. Rats were then lightly
anaesthetised, brains removed and their substantia nigra
dissected on ice. DA was estimated as previously described
[12] and TH activity estimated as outlined previously [8].
Data were subjected to one way ANOVA with a post hoc
Dunnett's test.
Rats treated with LPS and vehicle displayed characteristic
intense, 'tight' contraversive circling, following apomor-
phine (Fig 1) while those co-treated with intracerebral
UCN displayed much reduced apomorphine sensitivity.
UCN III did not attenuate apomorphine-induced circling
in lesioned rats (Fig 1). LPS treatment produced drastic
decreases in nigral DA which were substantially attenu-
ated when UCN was injected at the same time as the LPS
(Fig. 1) and critically, when UCN was given seven days fol-
lowing LPS injection. A similar pattern of reduction was
seen in nigral TH activity following LPS, and this was also
reversed by UCN either given at the same time and also
seven days post LPS injection (Fig. 1). In none of the
experiments did UCN III effect any decrease in LPS-
induced loss of tissue DA or TH activity. In order to estab-
lish whether these apparent reductions in 'Parkinsonian-
like' pathology were mediated by CRF receptors we co-
administered LPS and UCN with the non-selective CRF
receptor antagonist, α-helical CRF. α-helical CRF reversed
the 'protective' effects of UCN against LPS-induced loss of
DA, TH activity as well as apomorphine-induced circling
(Fig. 1). This clearly indicates that CRF receptors mediate
the actions of UCN. However, the CRF2 selective analogue
of UCN, UCN III was without effect. This logically indi-
cates that the protective actions of UCN are mediated by
CRF1 receptors.
The current findings demonstrate that UCN greatly atten-
uates the development of PD-like pathology in a recently
proposed [3,4] paradigm of the illness (LPS). The validity
of this model is being increasingly appreciated as the role
of neuroinflammation as a factor in the aetiology of PD is
gaining substantive support in patients and animal-mod-
els [3,4,13]. The ability to restore these indices of PD-like
damage in dopaminergic nigral neurons seven days after
administration of LPS is particularly significant. We have
determined that at this time point in our models the
lesion has become established but is evidently still unsta-
ble since degeneration continues to proceed for a least a
further seven days [8,14], Fig. 1. This is reasonably analo-
gous to the predicament of PD patients, where degenera-
tion proceeds until the nigrostriatal system is to all intents
destroyed as the illness reaches its terminal phase. Current
treatments are of limited, and purely symptomatic value,
becoming ineffective as the neurodegeneration proceeds.
What is clearly required is some treatment strategy whichJournal of Neuroinflammation 2007, 4:19 http://www.jneuroinflammation.com/content/4/1/19
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Effect of the CRF-like peptide UCN on indices of nigrostriatal damage induced by intranigral injection of LPS Figure 1
Effect of the CRF-like peptide UCN on indices of nigrostriatal damage induced by intranigral injection of LPS. Data were taken 
from rats 14 days after injection of LPS and UCN except where indicated (7 d post LPS) in which case UCN was given seven 
days after LPS injection. In some experiments rats were culled seven days after administration of LPS alone to indicate the 
development of lesion severity at this point. Indices assessed were as follows: upper panel, circling behaviour in response to 
the DA agonist apomorphine (one way ANOVA F = 7.763, p < 0.001); middle panel, nigral tissue DA concentration (F = 22.77, 
p < 0.001), lower panel, nigral tissue TH activity (F = 11.47, p < 0.001). Each group comprised 6–8 rats. In each case differ-
ences between groups were assessed using Bonferonni's multiple comparison test. *p < 0.05 versus groups treated with either 
LPS and vehicle or LPS and UCN III.
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either stabilizes the hostile conditions prevailing within
the SNc, or better, effects some degree of neuronal resto-
ration. Our data suggest that UCN may be able to achieve
this, probably acting via CRF1 sites. The observations with
UCN suggest that under neuroinflammatory conditions it
is able to elicit a functional recovery in nigrostriatal neu-
rotransmission. We have previously found UCN I to be
effective in restoring both striatal TH activity and DA con-
tent following either LPS or 6-OHDA-induced lesions
[8,14]. Futhermore, we have found that UCN I also
reverses loss of extracellular DA in the striatum of freely
moving rats (unpublished data). The resulting recovery in
nigral DA neurons presumably allows for a restoration of
D1 and D2 receptor balance in the striatum which would
logically underlie the recovery in 'normal' motor activity
(loss of circling) seen after apomorphine treatment. How-
ever, a determination of actual DA receptor population
would be required to prove this.
Evidence has shown that UCN protects some neurons via
activation of the CRF1 subtype [5,6], whilst activation of
CRF2 sites has been cited as important [10,15]. The possi-
bility that UCN can 'rescue' damaged cells has been pos-
tulated in some studies, especially cardiac myocytes [10]
and the heart ex vivo [11,16]. We are unclear as to the pre-
cise mechanism by which UCN I exerts its protective
effect. Our unpublished data indicates that UCN I treat-
ment leads to a preservation or restoration of TH+cells in
the SNc. Whether this is the result of cytoprotection, such
as might occur due to an anti-inflammatory action, or a
stimulation of neurogenesis remains to be determined.
One possibility could be that UCN I might reduce the
massive astrogliosis which arises in the SNc as a result of
LPS toxicity [17]. Additionally, the potential contribution
of the SNc relative to the ventral tegmental area in restor-
ing nigrostriatal function is also unclear, although we
intend to investigate this.
In summary, our data constitutes the first report of a res-
toration of key indicators of nigrostriatal damage in a neu-
roinflammatory model of PD after the lesion has become
established by a molecule known to have antiinflamma-
tory properties [7]. Although activation of the HPA axis by
a CRF agonist might have potentially deleterious side
effects, evidence suggests that these may be averted. Thus,
CRF and UCN both reduced weight gain in rodents but
CRF was much more effective than UCN in this respect
and only CRF produced effects consistent with increased
sympathetic activity[18]. In order to achieve substantial
therapeutic relevance a means by which central CRF1 sites
can be activated is clearly essential as may be refinement
to ensure an appropriate pharmacological response.
While UCN is a relatively large molecule with poor blood
brain barrier penetration, recently small, lippophillic,
CRF1 selective antagonists have become available and CRF
receptor pharmacology is a rapidly expanding field. As
such we consider it highly likely that CRF1 agonists will
become available offering new possibilities in the study of
UCN mediated neuroprotection as well as being of poten-
tial therapeutic value in PD.
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